cGMP is the floor, not the ceiling cGMP — current Good Manufacturing Practice — is the regulatory framework governing pharmaceutical manufacturing in the United States, codified in 21 CFR Parts 210 and 211. The regulations establish minimum requirements for personnel, facilities, equipment, production controls, laboratory controls, and records. They apply to every pharmaceutical manufacturer shipping product into the US market, regardless of where the manufacturing facility is located. The “minimum” designation matters. cGMP defines the baseline below which manufacturing is considered adulterated under the Federal Food, Drug, and Cosmetic Act. Companies that meet cGMP requirements are compliant. Companies that exceed them — through advanced process control, continuous monitoring, or AI-based quality systems — gain operational advantages without triggering additional regulatory burden. The regulatory ceiling is set by what the law forbids, not by what the law mandates as best practice. This distinction is the prerequisite for proportional compliance. Treat cGMP as a floor and you scope validation effort to what the regulation actually requires; treat it as an aspirational ceiling and you over-engineer auxiliary systems that have no GxP impact. We explain the broader boundary in What GxP Compliance Actually Requires for AI Software in Pharmaceutical Manufacturing. What cGMP compliance looks like in practice cGMP requirement What it means operationally Written procedures for production and process control Every manufacturing step has an approved SOP. Deviations from SOPs trigger formal investigation. Adequate building design and maintenance Facilities prevent contamination and mix-ups. Air handling, lighting, and plumbing meet defined specifications. Equipment calibration and maintenance All manufacturing equipment is qualified, calibrated on schedule, and maintained per documented procedures. Complete batch records Every batch has a traceable record documenting materials, process parameters, in-process tests, and final disposition. Laboratory testing before release Product is tested against predetermined specifications. Release requires documented quality unit approval. Trained personnel Operators are trained on relevant SOPs before performing manufacturing activities. Training is documented and current. The enforcement mechanism is FDA inspection. Inspectors review batch records, observe manufacturing operations, examine deviation investigations, and assess quality system effectiveness. Findings are documented as FDA Form 483 observations. Significant findings escalate to warning letters, consent decrees, or import alerts. The audit trail is not abstract — it is the same set of documents an inspector will physically pull from your archive on day one of an inspection. The documentation burden and its purpose cGMP’s documentation requirements are often criticised as excessive. Every batch record, every calibration log, every deviation report, every training record must be created, reviewed, approved, and archived. The purpose is not bureaucracy. The purpose is traceability — the ability to reconstruct exactly what happened during any manufacturing operation, identify the root cause of any quality issue, and demonstrate that quality decisions were made on data rather than assumption. For AI systems in pharmaceutical manufacturing, cGMP documentation obligations extend to model validation records, training data documentation, performance monitoring logs, and change control records for model updates. An AI system that makes quality-affecting decisions generates data that becomes part of the cGMP documentation framework — subject to the same retention, accessibility, and integrity requirements as any other GMP record. ALCOA+ data-integrity expectations (attributable, legible, contemporaneous, original, accurate, plus complete, consistent, enduring, and available) are not relaxed because the data originates from a neural network rather than a chromatograph. EU GMP Annex 11 complements cGMP’s documentation obligations with specific requirements for audit trails, electronic signatures, and data integrity controls in computerised systems. For multi-jurisdiction manufacturers, the practical compliance target is the union of 21 CFR Part 11 and Annex 11, not the intersection. Where AI reduces cGMP compliance cost The irony of cGMP’s documentation burden is that AI systems — when properly validated — can reduce it. Automated batch record generation eliminates transcription errors. Computer vision inspection, built on OpenCV or PyTorch-trained classifiers and deployed through ONNX or TensorRT runtimes, produces objective, reproducible results with complete image archives that survive inspection scrutiny better than subjective operator judgement. Environmental monitoring AI generates continuous data streams that eliminate the temporal gaps left by periodic manual sampling. The investment is upfront: validating the AI system, establishing the performance monitoring framework, documenting the training data and model architecture, and binding all of it into the site’s change-control regime. The return is ongoing — reduced manual documentation effort, fewer deviation investigations caused by human transcription error, and faster batch release cycles supported by automated data analysis. In our experience across GxP-regulated engagements, the deviation rate attributable to manual data entry is the single most under-counted cost that AI displaces; the savings show up not in the AI line item but in the deviation-investigation backlog. How do cGMP regulations apply to software and data systems? cGMP regulations apply to any computerised system that creates, modifies, maintains, archives, retrieves, or transmits data relating to pharmaceutical product quality. This scope encompasses laboratory information management systems (LIMS), manufacturing execution systems (MES), quality management systems (QMS), enterprise resource planning (ERP) modules handling batch records, and any custom data collection or analysis software used in GMP operations. The regulatory requirements for these systems derive from three sources: 21 CFR Part 211 (cGMP for finished pharmaceuticals), 21 CFR Part 11 (electronic records and electronic signatures), and FDA guidance documents on data integrity and computerised systems. EU-regulated sites additionally comply with EU GMP Annex 11 (computerised systems) and EU GMP Chapter 4 (documentation). The practical requirements for software systems: validated per a documented validation lifecycle, access controlled with user-specific credentials and role-based permissions, data protected by audit trails that record every modification with user identification and timestamp, electronic signatures implemented per 21 CFR Part 11 requirements, backup and restore procedures tested and documented, and a change-control process that assesses regulatory impact of every system change. We implement these requirements using a standardised architecture pattern: an application layer with role-based access control and electronic-signature workflow, a data layer with append-only audit trails and referential-integrity constraints, and an infrastructure layer — typically containerised with Docker and orchestrated on Kubernetes — with automated backup, monitoring, and alerting. This pattern is an observed pattern across our GxP engagements rather than a benchmarked rate; it reduces the implementation effort for new GMP systems by providing a pre-validated technical foundation that auditors recognise rather than reinterpret from scratch. Where the cGMP boundary actually sits cGMP does not regulate every piece of software running in a pharmaceutical company. A maintenance-ticketing system for non-GMP equipment, an HR portal, a marketing analytics tool — none of these fall in scope. The boundary is product-quality impact: does the system create, modify, or influence data on which a quality decision depends? If yes, it is in scope. If no, it is not, and treating it as if it were wastes validation budget that should be applied to systems that actually carry regulatory risk. For AI systems this boundary is sharper than for deterministic software, because the same model can be used in a GxP-critical role at one site and a purely advisory role at another. Scope is determined by use, not by the model. A vision model that gates batch release is GxP; the same model used as a non-binding alert for an operator who still performs the manual inspection of record is not. Documenting that distinction explicitly — in the system’s intended-use statement and the validation plan — is what separates a clean inspection from a 483. FAQ Which GxP roles own AI-specific risks and how is that documented? The system owner is accountable for fit-for-purpose use; QA owns release of the validation package and ongoing compliance oversight; the validation lead owns the validation lifecycle. AI-specific risks — training-data drift, model-performance degradation, explainability for deviation investigations — are documented in the system’s risk assessment and tracked through the quality management system like any other GMP risk.
